Dr. Will Howat is a highly respected scientist whose work has shaped IHC, ISH, and digital pathology for more than three decades. His contributions span medical research, respiratory disease, cancer biology, and veterinary science, with imaging and antibody validation at the core. Career highlights include identifying eosinophils in the lungs of infants who died of SIDS (1994), discovering pores in the basement membrane of patients with asthma (2001), and developing resin-based Tissue Microarrays (2010). A longtime advocate for digital pathology, he led a team creating AI models for IHC tissue recognition in 2019.

At Abcam, Dr. Will Howat has set global standards for antibody validation and characterization, introducing knockout cell specificity testing and biophysical QC, reducing variability and improving reproducibility across batches. He has authored 48 publications, with first-author work in The Lancet and contributions to Science, Nature, and other leading journals.

Dr Will Howat said: “It’s a fantastic honour to be recognised by CiteAb for a career spent driving and improving standards in IHC. I’ve always believed that high‑quality, well‑validated reagents are essential for meaningful scientific progress, and it’s incredibly rewarding to see that work contribute to advances such as spatial biology. Seeing Abcam antibodies play a role in helping researchers generate reliable insights, solve complex questions, and move discovery forward is a real privilege. This award reflects the effort of many people I’ve worked with over the years, and I’m proud to share it with colleagues across the scientific community who care deeply about reproducibility and the integrity of research.”

Josh Johnson, Vice President, Product Management & Strategy, also said: “I’m incredibly proud of our teams across Abcam, whose work underpins these recognitions. Dr Will Howat’s Significant Individual Impact award reflects the standards for Antibody validation and characterization, in particular in IHC, he has helped set across Abcam and the wider community. Coupled with our recognition as IHC Supplier Of The Year for Neuroscience and Phospho Antibodies recognition, this is a powerful endorsement of the quality and reliability our customers expect.”

Product recognitions

Abcam was also named “IHC Supplier of the Year in Neuroscience,” selected through citation data, reflecting the trust researchers place in our validated IHC tools to support high-quality neuroscience studies. The Company was also “Highly Commended – Phospho Antibody Supplier of the Year,” with performance in published research highlighting quality in a particularly challenging antibody class essential to signaling research.

Rhys Williams, Head of Antibody Data at CiteAb, said: “Reliable IHC antibodies are essential for advancing neuroscience research. This award win goes to show the impressive support of scientists working in this space. Congratulations to the Abcam team!”

Andrew Chalmers, CiteAb CEO and co-founder, also said: “Antibody validation is a field we care deeply about, and Will has been a driving force in moving it forward. I have seen how his work at Abcam makes a real difference to scientists relying on research antibodies every day, and is sure to have created a significant impact in the broader life science field. I was delighted when I heard the judges had selected him to win this year's award and send my congratulations to him and his team.”

www.abcam.com

Media Contacts:

Abcam

content@abcam.com

About CiteAb Awards

The CiteAb Awards celebrate the suppliers, products, and individuals driving progress and improving trust in global life science research. Using real‑world citation data and independent judging, the awards recognize companies and people whose work supports better experiments, stronger reproducibility, and more reliable science across disciplines.

For more information, visit https://www.citeab.com/awards

About Abcam

Abcam, a Danaher company, believes that the scientific community goes further, faster, when we go there together. We provide the research and clinical communities with expert scientific support, highly validated antibodies, assays, and other tools to address important targets in critical biological pathways. Today, we help 750,000 researchers in over 130 countries reach results faster in areas like cancer, neurological disorders, infectious diseases, and metabolic disorders.

Abcam is proud to be part of Danaher

Danaher’s science and technology leadership puts Abcam’s solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers.

Together with Danaher’s other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.

About Danaher

Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow.

Explore more at www.danaher.com.

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.